Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Zeiher, A.M.

Refine Results

Resource Type

Availability

Creation Date

Author

Show more

Language

Search results

  • RSS Feed
(1 - 20 of 21)

Pages

Lipoprotein(a) and the effect of alirocumab on revascularization after acute coronary syndrome
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes
Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab
Alirocumab after acute coronary syndrome in patients with a history of heart failure
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age
Cost-effectiveness of alirocumab in patients with acute coronary syndromes the ODYSSEY OUTCOMES trial
Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes
Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Pages